


# Supplemental Fig.1




**Figure S1**

**Specific decrease in monocytes in *Cebpb*<sup>-/-</sup> mice.**

(A) Frequencies of HSCs, CMPs, and GMPs among lineage<sup>-</sup> BM cells from WT or *Cebpb*<sup>-/-</sup> mice (n=5). (B) Absolute numbers (/ $\mu$ l) of Ly6C<sup>+</sup> and Ly6C<sup>-</sup> monocytes in PB of WT or *Cebpb*<sup>-/-</sup> mice (n=13). (C) Representative flow cytometric analysis of Ly6C<sup>+</sup> and Ly6C<sup>-</sup> monocytes in the spleen of WT or *Cebpb*<sup>-/-</sup> mice. (D) Frequencies of total, Ly6C<sup>+</sup> and Ly6C<sup>-</sup> monocytes in the spleen of WT (n=10) or *Cebpb*<sup>-/-</sup> (n=10) mice. (E) Absolute numbers of Ly6C<sup>+</sup> and Ly6C<sup>-</sup> monocytes in the spleen of WT (n=5) or *Cebpb*<sup>-/-</sup> (n=5) mice. Data are presented as mean  $\pm$  SD. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.

# Supplemental Fig.2




**Figure S2**

**Competitive BM transplantation reveals the cell-intrinsic requirement of C/EBP $\beta$  for monopoiesis.**

A total of  $5 \times 10^5$  BM cells from WT or *Cebpb*<sup>-/-</sup> mice (CD45.2<sup>+</sup>) together with  $5 \times 10^5$  WT BM cells (CD45.1<sup>+</sup>) were transplanted into lethally irradiated (8 Gy) WT recipient mice (CD45.1<sup>+</sup>). Six weeks later, BM and PB samples were analyzed by flow cytometry. Expression of CD45.1 and CD45.2 on the indicated monocyte subsets is shown. Chimerism of *Cebpb*<sup>-/-</sup> cells was significantly lower at the HSC level (unpublished observation). Therefore, the frequencies of CD45.2<sup>+</sup> test cells in the indicated monocyte subsets (middle panel) were calibrated according to CD45.2<sup>+</sup> chimerism among c-kit<sup>+</sup> Sca-1<sup>+</sup> lineage<sup>-</sup> HSCs (right panel). Data are presented as mean  $\pm$  SD. \*p<0.05, \*\*p<0.01.

# Supplemental Fig.3




**Figure S3**

**Specific targeting of monocytes in *Mx1-Cre* transgenic mice.**

(A) *Mx1* mRNA was upregulated during differentiation into monocytes. Quantitative RT-PCR of *Mx1* expression in HSCs, CMPs, GMPs, MDPs, cMoPs, Ly6C<sup>+</sup> monocytes, and Ly6C<sup>-</sup> monocytes purified from BM of WT mice by cell sorting (n=3). (B) *Cebpb* mRNA expression in the indicated cell populations obtained from BM of *Cebpb*<sup>fl/fl</sup> mice or mice produced by crossing *Cebpb*<sup>fl/fl</sup> mice with *Mx1-Cre* transgenic mice (n=3). (C) Frequencies of Ly6C<sup>+</sup> and Ly6C<sup>-</sup> monocytes in BM and PB of *Cebpb*<sup>fl/fl</sup> mice (n=6) or mice produced by crossing *Cebpb*<sup>fl/fl</sup> mice with *Mx1-Cre* transgenic mice (n=7). Data are presented as mean ± SD. \*p<0.05, \*\*p<0.01.

# Supplemental Fig.4




## Figure S4

### The cell cycle status of monocytes in the absence of C/EBP $\beta$ .

(A) Flow cytometric analysis of BrdU incorporation in MDPs, Ly6C<sup>+</sup> monocytes, and Ly6C<sup>-</sup> monocytes obtained from BM of WT or *Cebpb*<sup>-/-</sup> mice. (B) Frequencies of BrdU<sup>+</sup> cells in each population from WT or *Cebpb*<sup>-/-</sup> mice (n=3). (C and D) Ly6C<sup>+</sup> or Ly6C<sup>-</sup> monocytes were purified from WT (n=3) and *Cebpb*<sup>-/-</sup> (n=3) mice, fixed with ethanol, and subjected to cell cycle analysis using propidium iodide staining. The proportions of cycling cells (in S/G2/M phases) are shown. Data are presented as mean  $\pm$  SD. \*\*\*p<0.001.

# Supplemental Fig.5




**Figure S5**

**BrdU pulsing experiments reveal accelerated turnover of *Cebpb*<sup>-/-</sup> monocytes.**

Dynamics of monocyte subsets in WT and *Cebpb*<sup>-/-</sup> mice are shown. (A–D) Flow cytometric analysis of BrdU<sup>+</sup> among monocyte subsets from WT or *Cebpb*<sup>-/-</sup> mice after BrdU pulsing. Numbers indicate the percentage of cells in the adjacent boxed area. Negative controls were WT mice not injected with BrdU.

# Supplemental Fig.6




## Figure S6

### Death of Ly6C<sup>-</sup> monocytes is accelerated in *Cebpb*<sup>-/-</sup> mice.

Mouse PB cells were stained using the MitoPTJC-1 Assay Kit (ImmunoChemistry Technologies, MN, USA) according to the manufacturer's protocols after staining for cell surface markers. Mitochondrial red fluorescence and cytoplasmic green fluorescence were analyzed using a FACSCantoll instrument. APC-conjugated anti-CD11b (M1/70), PE-Cy7-conjugated anti-F4/80 (BM8), and V450-conjugated anti-Ly6C antibodies were used. CD11b<sup>+</sup> F4/80<sup>+</sup> FSC<sup>low-int</sup> SSC<sup>low</sup> cells were defined as monocytes in this experiment. (A) Mitochondrial membrane potential of Ly6C<sup>-</sup> monocytes from WT and *Cebpb*<sup>-/-</sup> mice. Numbers indicate the percentage of cells with normal (dotted lines) and depolarized (filled lines) mitochondria. (B) Frequencies of Ly6C<sup>-</sup> monocytes with depolarized (apoptotic) mitochondria from WT and *Cebpb*<sup>-/-</sup> mice (n=6). Data are presented as mean ± SD.

## Supplemental Fig.7




### Figure S7

**The serum Csfl level is identical in WT and *Cebpb*<sup>-/-</sup> mice.**

The Csfl level in serum samples obtained from WT (n=6) and *Cebpb*<sup>-/-</sup> (n=7) mice was measured using an ELISA. Data are presented as mean  $\pm$  SD.

# Supplemental Fig.8




**Figure S8**

mRNA expression of molecules known to be required for the development of Ly6C<sup>-</sup> monocytes.

(A and B) mRNA expression of *Nr4a1*, *Cx3cr1*, and *S1pr5* in the indicated cell populations (n=3). Data are presented as the mean ± SD. \*\*\*p<0.001.



## Supplemental Fig.9



### Figure S9

#### Egress of Ly6C<sup>-</sup> monocytes from BM is not impaired in *Cebpb*<sup>-/-</sup> mice.

To label cells in BM sinusoids, mice were intravenously injected with a PE-conjugated anti-CD45 antibody and sacrificed 2 min later. BM was then analyzed by flow cytometry. The percentages of CD45<sup>+</sup> cells within the indicated monocyte subsets are shown. Data are presented as mean  $\pm$  SD.

**Supplementary Table 1: Primers used for quantitative real-time PCR**

Primer sequences (in 5'-3' direction) and TaqMan probes (Universal Probe Library, Roche Diagnostics) used for quantitative real-time PCR.

Gene name	Forward primer	Reverse primer	Universal probe No.
<i>Cebpb</i>	ATCGACTTCAGCCCCTACCT	TAGTCGTCGGCGAAGAGG	55
<i>Nr4a1</i>	AGCTTGGGTGTTGATGTTCC	AATGCGATTCTGCAGCTCTT	1
<i>S1pr5</i>	GGAGTGCCGGTTACAGGAG	GAAGGACAATAACCTCACTCACC	70
<i>Ccr2</i>	ACCTGTAAATGCCATGCAAGT	TGTCTTCCATTTCTTTGATTTG	27
<i>Cx3cr1</i>	AAGTTCCTTCCCATCTGCT	CAAATTCTCTAGATCCAGTTCAGG	10
<i>Mx1</i>	TTCAAGGATCACTCATACTTCAGC	GGGAGGTGAGCTCCTCAGT	53
<i>Gpadh</i>	TGTCCGTCGTGGATCTGAC	CCTGCTTCACCACCTTCTTG	80